Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2463-2467

  Groll, Andreas H ^a   Petraitis, Vidmantas ^a   Petraitiene, Ruta ^a   Field Ridley, Aida ^a   Calendario, Myrna ^a   Bacher, John ^b   Piscitelli, Stephen C ^c   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE; LIPOSOME; NYSTATIN;

ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0032820093     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2463     Document Type: Article

References (35)

1. Anaissie, E. J., J. H. Rex, O. Uzun, and S. Vartivarian. 1998. Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med. 104:238-245.
2. Berenguer, J., M. Buck, F. Witebsky, F. Stock, P. A. Pizzo, and T. J. Walsh. 1993. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Diagn. Microbiol. Infect. Dis. 17:103-109.
3. Besnard, M., O. Hartmann, D. Valteau-Couanet, M. Robert, L. Brugieres, and J. Lemerle. 1993. Systemic Candida infection in pediatric BM-autotransplantation: clinical signs, outcome and prognosis. Bone Marrow Transplant. 11:465-470.
4. Boutati, E., H. C. Maltezou, G. Lopez-Berestein, S. E. Vartivarian, and E. Anaissie. 1995. Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with haematological malignancies, abstr. LM22, p. 330. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
6. Cossum, P. A., J. Wyse, Y. Simmons, T. L. Wallace, and A. Rios. 1996. Pharmacokinetics of Nyotran (liposomal nystatin) in human patients, abstr. A88, p. 17. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Edwards, J. E., G. P. Bodey, R. A. Bowden, T. Buchner, B. E. de Pauw, S. G. Filler, M. A. Ghannoum, M. Glauser, R. Herbrecht, C. A. Kauffman, S. Kohno, P. Martino, F. Meunier, T. Mori, M. A. Pfaller, J. H. Rex, T. R. Rogers, R. H. Rubin, J. Solomkin, C. Viscoli, T. J. Walsh, and M. White. 1997. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin. Infect. Dis. 25:43-59.
8. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, and D. J. Friedman. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
9. Goodrich, J. M., E. C. Reed, M. Mori, L. D. Fisher, S. Skerrett, P. S. Dandliker, B. Klis, G. W. Counts, and J. D. Meyers. 1991. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J. Infect. Dis. 164:731-740.
10. Gordon, D., I. Baird, R. Darouiche, V. Fainstein, L. Juaregui, C. Levy, and P. Lewis. 1997. Liposomal nystatin vs. amphotericin B for candidemia in non-neutropenic patients: a historical comparison, abstr. 144, p. 98. In Program and abstracts of the 35th Meeting of the Infectious Diseases Society of America. Infectious Diseases Society of America, Arlington, Va.
11. Gosh, B. K., and A. Gosh. 1967. The effects of antibiotics on Leishmania donovanii. Dermatol. Int. 6:154-160.
12. Groll, A. H., C. E. Gonzalez, N. Giri, K. Kligys, W. Love, J. Peter, E. Feuerstein, J. Bacher, S. C. Piscitelli, and T. J. Walsh. 1999. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety, and non-compartmental pharmacokinetics. J. Antimicrob. Chemother. 43:95-103.
13. Groll, A. H., D. Mickiene, R. Petraitiene, V. Petraitis, M. Candelario, A. Field-Ridley, J. Bacher, S. Piscitelli, and T. J. Walsh. 1998. Compartmental pharmacokinetics and tissue distribution of liposomal nystatin in rabbits, abstr. J-60, p. 468. In Program and abstracts of the 38h Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Groll, A. H., D. Mickiene, K. Werner, S. C. Piscitelli, and T. J. Walsh. High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies. J. Chromatogr., in press.
15. Groll, A. H., P. M. Shah, C. Mentzel, M. Schneider, G. Just-Nuebling, and K. Huebner. 1996. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33:23-32.
16. Groll, A. H., S. C. Piscitelli, and T. J. Walsh. 1998. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44:343-500.
17. Hamilton-Miller, J. M. T. 1973. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol. Rev. 37:166-196.
18. Hazen, E. L., and R. Brown. 1950. Two antifungal agents produced by a soil actinomycete. Science 112:423.
19. Kleinberg, M. E., and A. Finkelstein. 1984. Single-length and double-length channels formed by nystatin in lipid bilayer membranes. J. Membr. Biol. 80:257-269.
20. Klingspor, L., G. Stintzing, A. Fasth, and J. Tollemar. 1996. Deep Candida infection in children receiving allogeneic bone marrow transplants: incidence, risk factors and diagnosis. Bone Marrow Transplant. 17:1043-1049.
21. Lecciones, J. A., J. W. Lee, E. E. Navarro, F. G. Witebsky, D. Marshall, S. M. Steinberg, P. A. Pizzo, and T. J. Walsh. 1992. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin. Infect. Dis. 14:875-883.
22. Marina, M. N., P. N. Flynn, G. K. Rivera, and W. T. Hughes. 1991. Candida tropicalis and Candida albicans fungemia in children with leukemia. Cancer 68:594-599.
23. Mehta, R. T., R. L. Hopfer, L. A. Gunner, R. L. Juliano, and G. Lopez-Berestein. 1987. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31:1897-1900.
24. Mehta, R. T., R. L. Hopfer, T. McQueen, R. L. Juliano, and G. Lopez-Berestein. 1987. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 31:1901-1903.
25. Meunier, F., M. Aooun, and N. Bitar. 1992. Candidemia in immunocompromised patients. Clin. Infect. Dis. 14(Suppl. 1):S120-S125.
26. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
27. Rolston, K., I. Baird, D. R. Graham, and L. Jauregui. 1998. Treatment of refractory candidemia in non-neutropenic patients with liposomal nystatin (Nyotran™), abstr. LB-1, p. 24. In Program and abstracts of the 38h Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
28. Wallace, T. L., V. Paetznick, P. A. Cossum, G. Lopez-Berestein, J. H. Rex, and E. Anaissie. 1997. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother. 41:2238-2243.
29. Walsh, T. J., C. McEntee, and D. M. Dixon. 1987. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J. Clin. Microbiol. 25:931-932.
30. Walsh, T. J., J. W. Lee, E. Roilides, P. Francis, J. Bacher, C. A. Lyman, and P. A. Pizzo. 1992. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin. Infect. Dis. 14(Suppl. 1):S139-S147.
31. Walsh, T. J., P. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38:467-470.
32. Walsh, T. J., R. W. Finberg, C. Arndt, J. Hiemenz, C. Schwartz, D. Bodensteiner, P. Pappas, N. Seibel, R. N. Greenberg, S. Dummer, M. Schuster, J. S. Holcenberg, and W. E. Dismukes. 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 340:764-761.
33. Walsh, T. J., S. Aoki, F. Mechinaud, J. Bacher, J. Lee, M. Rubin, and P. A. Pizzo. 1990. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J. Infect. Dis. 161:755-760.
34. Wasan, K. M., M. Ramaswami, S. M. Cassidy, M. Kazemi, F. W. Strobel, and R. L. Thies. 1997. Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob. Agents Chemother. 41: 1871-1875.
35. Winston, D. J., P. H. Chandrasekar, H. M. Lazarus, J. L. Goodman, J. L. Silber, H. Horowitz, R. K. Shadduck, C. S. Rosenfeld, W. G. Ho, and M. Z. Islam. 1993. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized, placebo-controlled, double-blind multicenter trial. Ann. Intern. Med. 118:495-503.